leisure time -WSS

leisure time

author：comprehensive 2025-08-28 02:51:19 - browse：8

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： HIV vaccine remains elusive. Immunologists keep trying new ideas

WSS

STAT Summit: Biotech founders on deal

Lawmakers consider Medicare pay reforms for doctors

HIV vaccine remains elusive. Immunologists keep trying new ideas

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Arc Institute generative AI designs new CRISPR systems

focus

leisure time

explore

In Memoriam: Notable people who died in 2023

Readers respond to H5N1 and livestock movements, and more

The cancer drug shortage isn’t new — and neither are the solutions

Solve the antibiotic resistance crisis with preventive drugs

As demand for Covid shots wanes, Moderna seeks its next success

Pharmacists can make shortage drugs, but at what cost?

23andMe had bad news about my health. I wish a person had delivered it

Cytokinetics CEO stresses company can launch heart drug on its own

Psychedelics group wrestles with new pharma identity

First Opinion Podcast: Long Covid needs a new approach

leisure time

Data integrity in scientific journals requires "effort" by publishers, institutions

Criminal prosecution for violating HIPAA: an emerging threat

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Impact of Dobbs ruling felt at reproductive medicine meeting

STAT Summit: Biotech founders on deal

Wikipedia

entertainment

focus

hotspot